Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Completed · Phase 2 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus (RSV)

In brief

The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.

Key facts

Study ID

NCT02534350

Run by

Gilead Sciences

People needed

61

Starts

2015-12-31

Expected to finish

2017-09-27

Last updated by the study team

2018-11-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — San Francisco, California, United States
• Study site — Stanford, California, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Maywood, Illinois, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Cleveland, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Dallas, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Seattle, Washington, United States
• Study site — Sydney, New South Wales, Australia
• Study site — Brisbane, Queensland, Australia
• Study site — Murdoch, Western Australia, Australia
• Study site — Brussels, Belgium
• Study site — Yvoir, Belgium
• Study site — Toronto, Ontario, Canada
• Study site — Strasbourg, France
• Study site — Hanover, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.